President Donald Trump announced Thursday that he is nominating Chris Klomp to serve as deputy secretary of the Department of Health and Human Services. In his Truth Social post, Trump praised Klomp and said he and HHS Secretary Robert F. Kennedy Jr. and CMS Administrator Dr. Mehmet Oz made the decision together.
Trump described Klomp as a “potential STAR” with a “rapid rise” inside the administration. Those promotional statements are assertions by the president and are not independently verified in this report.
What Trump announced
In a Truth Social post, Trump called Chris Klomp a “Strong and Inspiring Leader” and said Klomp’s experience running Medicare operations made him a natural choice for deputy secretary. The post noted that Secretary Robert F. Kennedy Jr. and Dr. Mehmet Oz joined the decision.
Trump also credited Klomp with helping to implement drug pricing changes, saying “Our Drug Prices have come down MASSIVELY in the last year.” Those claims are presented here as assertions by the president and have not been independently verified for this article.
Administration statements frame the pick as an operational move—placing a veteran of internal program management into a top management post. Independent reporting and documentation to corroborate all of the president’s evaluations of Klomp’s record are limited at this time; readers should regard the praise as the administration’s assessment.
Who is Chris Klomp
According to his LinkedIn profile, Chris Klomp holds or has held senior roles tied to HHS and Medicare: Chief Counselor of HHS, Deputy Administrator of the Centers for Medicare & Medicaid Services (CMS), Director of the Center for Medicare at CMS, and Senior Advisor to the Secretary of HHS. Those titles are self-reported on LinkedIn.
The profile describes duties that include oversight of Medicare operations and working on implementation of programmatic changes. This article cites those LinkedIn-listed roles as self-reported; independent confirmation of every line on the profile is not available here.
Public records and formal agency biographies can sometimes lag behind private profiles, and nominees commonly present experience on platforms like LinkedIn. Reporters and Senate offices typically request official résumés, ethics disclosures and personnel records during the confirmation process to verify backgrounds.
Policy record and claims
Trump’s post credited Klomp with driving what the president called “historic” reforms — most prominently the administration’s embrace of the MOST FAVORED NATION drug pricing approach. The president framed that policy as a major factor in lowering U.S. drug costs.
Most Favored Nation policies tie certain Medicare drug payment rates to prices paid in other countries. Proponents say the approach can reduce what Medicare—and therefore taxpayers and beneficiaries—pay for some medicines. Critics warn of potential supply, market or legal consequences and say the full effects can take time to measure.
The White House assertion that drug prices have fallen “MASSIVELY” under the policy is presented here as an unverified claim by President Trump. Independent analysts and outside health-economics experts offer differing estimates about the scale and timing of any savings from complex pricing reforms, and some impacts may depend on follow-up rules, contracting and litigation.
Reporting on the nominee does not adjudicate the causal effect of a single official’s actions on nationwide price trends. The article notes only that the White House attributes elements of the policy rollout to Klomp; further confirmation would come through documents, public records and congressional review.
What this could mean for HHS and Medicare
If confirmed, a deputy secretary with Klomp’s described background would most likely emphasize operational oversight: ensuring Medicare programs run smoothly, implementing pricing directives, and coordinating between HHS leadership and CMS program teams.
Practical priorities could include accelerating implementation of existing pricing rules, strengthening internal monitoring and compliance, and directing staff on program-level changes tied to drug pricing and beneficiary access. A deputy secretary also manages cross-agency coordination and personnel focused on day-to-day operations.
Because drug pricing intersects with procurement, trade considerations and legal challenges, expect HHS to weigh expanded enforcement steps alongside engagement with stakeholders—manufacturers, insurers, state officials and Congress. Any rapid operational shifts could raise questions from Capitol Hill and outside groups about impacts on access and markets.
Next steps and confirmation process
The White House will transmit Klomp’s formal nomination to the Senate. The nomination is typically referred to the Senate Health, Education, Labor and Pensions (HELP) Committee or the relevant panel for hearings, document production and background reviews before a committee vote and potential full-Senate floor vote.
Committee staff will likely request written materials, and the Senate may hold public hearings where Klomp would answer questions about his qualifications, management approach and policy priorities. Timelines vary; the process can take weeks to months depending on the Senate calendar and any contested issues.
Senators and outside groups may scrutinize both the administration’s policy claims and the details of Klomp’s resume. Confirmation outcomes will hinge on committee deliberations, votes and floor scheduling in the Senate.
Source attribution
This report is based on the White House announcement and the administration’s Truth Social post, with background drawn from Chris Klomp’s LinkedIn profile. For the White House announcement and original reporting, see Fox News: https://www.foxnews.com/politics/trump-chris-klomp-hhs-deputy-secretary.
Frequently asked questions
Who is Chris Klomp?
Chris Klomp is President Trump’s nominee for HHS deputy secretary. His LinkedIn lists roles including Chief Counselor of HHS, Deputy Administrator at CMS and Director of the Center for Medicare. Those roles are self-reported on his profile and are noted here as such.
What is the MOST FAVORED NATION policy?
The MOST FAVORED NATION approach referenced by the White House ties some Medicare drug payment rates to lower prices paid in other countries. The administration says it lowers costs; that claim is presented in this article as an assertion by the president and is not independently confirmed here.
What are the next steps for the nomination?
The White House will transmit the formal nomination to the Senate, where it will typically go to the appropriate committee for hearings, document reviews and a committee vote before the full Senate considers confirmation.
